Simulations to compare efficacies of tetravalent dengue vaccines and mosquito vector control

Epidemiology and Infection

Volumn 142, Issue 6, 2014, Pages 1245-1258

  Thavara, U ^a   Tawatsin, A ^a   Nagao, Y ^b  

^a MINISTRY OF PUBLIC HEALTH   (Thailand)

^b Onoda Hospital   (Japan)

Author keywords

Dengue haemorrhagic fever; mathematical modelling; vaccine safety; vaccines; vector control

Indexed keywords

DENGUE VACCINE;

ARTICLE; COMPUTER SIMULATION; CONTROLLED STUDY; DENGUE; DISEASE CONTROL; DISEASE TRANSMISSION; HEALTH PROGRAM; INCIDENCE; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MOSQUITO; NONHUMAN; POPULATION ABUNDANCE; POPULATION GROWTH; SEASONAL VARIATION; SEROCONVERSION; VACCINATION; VECTOR CONTROL;

ADOLESCENT; ADULT; AGING; ANIMALS; CHILD; CHILD, PRESCHOOL; COMPUTER SIMULATION; CULICIDAE; DENGUE; DENGUE VACCINES; HUMANS; IMMUNIZATION PROGRAMS; INFANT; MIDDLE AGED; MODELS, BIOLOGICAL; MOSQUITO CONTROL; SEASONS; THAILAND; VACCINATION; YOUNG ADULT;

EID: 84898616578     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268813001866     Document Type: Article

References (51)

1. Kalayanarooj S. Standardized clinical management: evidence of reduction of dengue haemorrhagic fever case-fatality rate in Thailand. Dengue Bulletin 1999; 23: 10-17.
2. WHO Regional Office for South-East Asia. Dengue/DHF: case fatality rate (%) of DF/DHF in the SouthEast Asia Region (1985-2006). (http://www.searo. who.int/en/Section10/Section332-1102.htm). Accessed 24 September 2007.
3. Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. New York: Oxford University Press, 1991.
4. Dantes HG, et al. Dengue epidemics on the Pacific Coast of Mexico. International Journal of Epidemiology 1988; 17: 178-186.
5. Egger JR, Coleman PG. Age and clinical dengue illness. Emerging Infectious Diseases 2007; 13: 924-925.
6. Egger JR, et al. Reconstructing historical changes in the force of infection of dengue fever in Singapore: implications for surveillance and control. Bulletin of the World Health Organization 2008; 86: 187-196.
7. Guha-Sapir D, Schimmer B. Dengue fever: new paradigms for a changing epidemiology. Emerging Themes in Epidemiology 2005; 2: 1.
8. Coleman PG, Perry BD, Woolhouse ME. Endemic stability-A veterinary idea applied to human public health. Lancet 2001; 357: 1284-1286.
9. Nagao Y, Koelle K. Decreases in dengue transmission may act to increase the incidence of dengue hemorrhagic fever. Proceedings of the National Academy of Sciences USA 2008; 105: 2238-2243.
10. Halstead SB, Shotwell H, Casals J. Studies on the pathogenesis of dengue infection in monkeys. II. Clinical laboratory responses to heterologous infection. Journal of Infectious Diseases 1973; 128: 15-22.
11. Sabin AB. Research on dengue during World War II. American Journal of Tropical Medicine and Hygiene 1952; 1: 30-50.
12. Sangkawibha N, et al. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. American Journal of Epidemiology 1984; 120: 653-669.
13. Thammapalo S, et al. Relationship between transmission intensity and incidence of dengue hemorrhagic fever in Thailand. PLoS Neglected Tropical Diseases 2008; 2: e263.
14. Sun W, et al. Phase 2 clinical trial of three formulations of tetravalent live-Attenuated dengue vaccine in flavivirus-naive adults. Human Vaccines 2009; 5: 33-40.
15. Guy B, et al. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine. Vaccine 2011; 29: 7229-7241.
16. Sabchareon A, et al. Protective efficacy of the recombi-nant, live-Attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380: 1559-1567.
17. Morens DM. Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clinical Infectious Diseases 1994; 19: 500-512.
18. Huisman W, et al. Vaccine-induced enhancement of viral infections. Vaccine 2009; 27: 505-512.
19. Guy B, et al. Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-Attenuated tetravalent dengue vaccine. Vaccine 2004; 22: 3563-3574.
20. Poo J, et al. Live-Attenuated tetravalent dengue vaccine in dengue-naive children, adolescents, and adults in Mexico City: randomized controlled phase 1 trial of safety and immunogenicity. Pediatric Infectious Disease Journal 2011; 30: e9-e17.
21. Morrison D, et al. A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 sero-types in flavivirus-naive adults. Journal of Infectious Diseases 2010; 201: 370-377.
22. Beatty M, et al. Assessing the potential of a candidate dengue vaccine with mathematical modeling. PLoS Neglected Tropical Diseases 2012; 6: e1450.
23. Grimm V, et al. Pattern-oriented modeling of agent-based complex systems: lessons from ecology. Science 2005; 310: 987-991.
24. Kliks SC, et al. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. American Journal of Tropical Medicine and Hygiene 1988; 38: 411-419.
25. Brandt WE, et al. Infection enhancement of dengue type 2 virus in the U-937 human monocyte cell line by antibodies to flavivirus cross-reactive determinants. Infection and Immunity 1982; 36: 1036-1041.
26. Morens DM, Halstead SB, Marchette NJ. Profiles of antibody-dependent enhancement of dengue virus type 2 infection. Microbial Pathogenesis 1987; 3: 231-237.
27. Guirakhoo F, et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Human Vaccines 2006; 2: 60-67.
28. Anderson KB, et al. A short time interval between first and second dengue infections is associated with protection from clinical illness in a prospective school-based cohort in Thailand. In: Annual Meeting of the American Society of Tropical Medicine and Hygiene, Atlanta, GA, USA, 2012.
29. Guzman MG, et al. Epidemiologic studies on dengue in Santiago de Cuba, 1997. American Journal of Epidemiology 2000; 152: 793-799; discussion 804.
30. Gonzalez D, et al. Classical dengue hemorrhagic fever resulting from two dengue infections spaced 20 years or more apart: Havana, Dengue 3 epidemic, 2001-2002. International Journal of Infectious Diseases 2005; 9: 280-285.
31. Vaughn DW, et al. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. Journal of Infectious Diseases 2000; 181: 2-9.
32. Wearing HJ, Rohani P. Ecological and immunological determinants of dengue epidemics. Proceedings of the National Academy of Sciences USA 2006; 103: 11802-11807.
33. Chikaki E, Ishikawa H. A dengue transmission model in Thailand considering sequential infections with all four serotypes. Journal of Infection in Developing Countries 2009; 3: 711-722.
34. Massad E, et al. Dengue and the risk of urban yellow fever reintroduction in Sao Paulo State, Brazil. Revista de Saude Publica 2003; 37: 477-484.
35. Coelho GE, et al. Dynamics of the 2006/2007 dengue outbreak in Brazil. Memorias do Instituto Oswaldo Cruz 2008; 103: 535-539.
36. Macdonald G. The analysis of equilibrium in malaria. Tropical Diseases Bulletin 1952; 49: 813-829.
37. Macdonald G. The Epidemiology and Control of Malaria. Oxford: Oxford University Press, 1957.
38. Ferguson NM, Donnelly CA, Anderson RM. Transmission dynamics and epidemiology of dengue: insights from age-stratified sero-prevalence surveys. Philosophical Transactions of the Royal Society of London, Series B: Biological Sciences 1999; 354: 757-768.
39. Johansson MA, Hombach J, Cummings DA. Models of the impact of dengue vaccines: a review of current research and potential approaches. Vaccine 2011; 29: 5860-5868.
40. Gubler DJ, et al. Viraemia in patients with naturally acquired dengue infection. Bulletin of the World Health Organization 1981; 59: 623-630.
41. Hombach J, et al. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005; 23: 5205-5211.
42. Strickman D, Kittayapong P. Dengue and its vectors in Thailand: introduction to the study and seasonal distribution of Aedes larvae. American Journal of Tropical Medicine and Hygiene 2002; 67: 247-259.
43. Russel J, Cohn R. Total Fertility Rate. Edinburgh: Lennex Corp, 2012.
44. Epstein JM, et al. Toward a Containment Strategy for Smallpox Bioterror: An Individual-based Computational Approach. Washington, D.C.: Brookings Institution Press, 2004.
45. Vardavas R, Breban R, Blower S. Can influenza epidemics be prevented by voluntary vaccination? PLoS Computational Biology 2007; 3: e85.
46. Morimoto T, Ishikawa H. Assessment of intervention strategies against a novel influenza epidemic using an individual-based model. Environmental Health and Preventive Medicine 2010; 15: 151-161.
47. Focks DA, Chadee DD. Pupal survey: an epidemiologi-cally significant surveillance method for Aedes aegypti: an example using data from Trinidad. American Journal of Tropical Medicine and Hygiene 1997; 56: 159-167.
48. Manrique-Saide P, et al. Pupal surveys for Aedes aegypti surveillance and potential targeted control in residential areas of Merida, Mexico. Journal of the American Mosquito Control Association 2008; 24: 289-298.
49. Knudsen AB, Slooff R. Vector-borne disease problems in rapid urbanization: new approaches to vector control. Bulletin of the World Health Organization 1992; 70: 1-6.
50. Reiter P, Gubler DJ. Surveillance and control of urban dengue vectors. In: Gubler DJ, Kuno G, eds. Dengue and Dengue Hemorrhagic Fever. Wallingford: CAB International, 1998, pp. 425-462.
51. Massad E, et al. A model-based design of a vaccination strategy against rubella in a non-immunized community of Sao Paulo State, Brazil. Epidemiology and Infection 1994; 112: 579-594.